Mallory Baker
Internal Medicine · Louisville, KYNPI 1518209089
Payments from drug & device makers
Across 97 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$393
- AbbVie$330
- Sanofi-aventis U.S. LLC$88
- AstraZeneca$70
- Lilly USA, LLC$67
- Exact Sciences$65
- plus $698 from 22 others
What the payments were for
- Food & beverage$1,711100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $393 |
| AbbVie | 16 | $330 |
| Sanofi-aventis U.S. LLC | 6 | $88 |
| AstraZeneca | 5 | $70 |
| Lilly USA, LLC | 5 | $67 |
| Exact Sciences | 4 | $65 |
| Xeris Pharmaceuticals, Inc. | 3 | $64 |
| Bayer | 3 | $60 |
| Pfizer | 3 | $57 |
| Inspire Medical Systems, Inc. | 2 | $54 |
| GSK | 3 | $46 |
| Cranial Technologies, Inc | 3 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $42 |
| Amarin Pharma, Inc. | 2 | $40 |
| Novartis | 2 | $37 |
| Ironshore Pharmaceuticals Inc. | 3 | $37 |
| Nevro Corp. | 1 | $26 |
| VBI Vaccine (delaware) Inc. | 1 | $24 |
| Amgen | 1 | $21 |
| Lundbeck LLC | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Angiodynamics, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Endogastric Solutions, Inc | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Sobi, Inc | 1 | $13 |
| Eisai Inc. | 1 | $12 |
| Boehringer Ingelheim | 1 | $11 |
How this compares
$1,711 in reported general payments places this provider in the 70th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 45 | $45,330 |
| OzempicSemaglutide | 35 | $41,427 |
| TrulicityDulaglutide | 19 | $31,064 |
| JanuviaSitagliptin Phosphate | 22 | $24,525 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $23,739 |
| MounjaroTirzepatide | 20 | $20,499 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $14,478 |
| JardianceEmpagliflozin | 11 | $12,859 |
| XareltoRivaroxaban | 16 | $12,827 |
| Atorvastatin Calcium | 470 | $5,382 |
| Levothyroxine Sodium | 366 | $3,374 |
| Duloxetine Hcl | 94 | $2,993 |
| Omeprazole | 183 | $2,874 |
| Losartan Potassium | 234 | $2,827 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 88 | $2,382 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $67 | $51,56339 claims |
| PfizerEliquis | $57 | $45,33045 claims |
| Novo NordiskOzempic | $393 | $41,42735 claims |
| GSKTrelegy Ellipta | $46 | $14,47819 claims |
| Boehringer IngelheimJardiance | $11 | $12,85911 claims |
| AbbVieSynthroid, Armour Thyroid | $330 | $2,27129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Louisville
- Jason ChesneyLouisville$6.3M
- Robert SasserLouisville$62K
- Kelley McIntyreLouisville$48K
- Lal TanwaniLouisville$38K
- Mark WilliamsLouisville$33K
- Scott YoungLouisville$24K
- Frank SimonLouisville$22K
- Walter BruningLouisville$22K
- Brian ParadowskiLouisville$20K
- Suresh NairLouisville$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.